Tamar Rachmilewitz Minei

Safety and efficacy of VB-111, an anticancer gene therapy, in patients with recurrent glioblastoma: results of a phase I/II study

P. Wen, T. Cloughesy, L. Freedman, 2019, Neuro-oncology.

A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE)

P. Wen, T. Cloughesy, N. Butowski, 2019, Neuro-oncology.

Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect.

M. Birrer, D. Harats, R. Arend, 2020, Gynecologic oncology.